Beyondspring Inc
BYSI2.170USD
+0.100+4.83%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
87.49MCap. mercado
PérdidaP/E TTM
Más Datos de Beyondspring Inc Compañía
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Información de la empresa
Símbolo de cotizaciónBYSI
Nombre de la empresaBeyondspring Inc
Fecha de salida a bolsaMar 09, 2017
Director ejecutivoDr. Lan Huang, Ph.D.
Número de empleados40
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 09
Dirección100 Campus Drive, West Side, 4Th Floor
CiudadFLORHAM PARK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal07932
Teléfono16465284184
Sitio Webhttps://www.beyondspringpharma.com/en/
Símbolo de cotizaciónBYSI
Fecha de salida a bolsaMar 09, 2017
Director ejecutivoDr. Lan Huang, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lan Huang, Ph.D.
Dr. Lan Huang, Ph.D.
Chairperson of the Board, Chief Executive Officer, Co-Founder
Chairperson of the Board, Chief Executive Officer, Co-Founder
4.26M
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Independent Director
Independent Director
53.86K
+119.03%
Dr. Jiangwen (Jen) Majeti, Ph.D.
Dr. Jiangwen (Jen) Majeti, Ph.D.
Independent Director
Independent Director
50.91K
--
Dr. June Lu, Ph.D.
Dr. June Lu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Sihai Xu
Mr. Sihai Xu
Director
Director
--
--
Mr. Brendan P. Delaney
Mr. Brendan P. Delaney
Independent Director
Independent Director
--
--
Mr. Matthew Kirkby
Mr. Matthew Kirkby
Independent Director
Independent Director
--
-100.00%
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lan Huang, Ph.D.
Dr. Lan Huang, Ph.D.
Chairperson of the Board, Chief Executive Officer, Co-Founder
Chairperson of the Board, Chief Executive Officer, Co-Founder
4.26M
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Independent Director
Independent Director
53.86K
+119.03%
Dr. Jiangwen (Jen) Majeti, Ph.D.
Dr. Jiangwen (Jen) Majeti, Ph.D.
Independent Director
Independent Director
50.91K
--
Dr. June Lu, Ph.D.
Dr. June Lu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Sihai Xu
Mr. Sihai Xu
Director
Director
--
--
Mr. Brendan P. Delaney
Mr. Brendan P. Delaney
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 19 de jul
Actualizado: sáb., 19 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Decheng Capital LLC
12.11%
Huang (Lan)
10.58%
Jia (Linqing)
4.43%
The Vanguard Group, Inc.
1.30%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
71.30%
Accionistas
Accionistas
Proporción
Decheng Capital LLC
12.11%
Huang (Lan)
10.58%
Jia (Linqing)
4.43%
The Vanguard Group, Inc.
1.30%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
71.30%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
15.26%
Venture Capital
12.11%
Investment Advisor
1.69%
Investment Advisor/Hedge Fund
0.35%
Hedge Fund
0.13%
Bank and Trust
0.09%
Research Firm
0.03%
Other
70.33%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
62
11.96M
29.67%
-626.00K
2025Q1
65
11.44M
28.38%
-1.18M
2024Q4
71
11.41M
28.30%
-5.42M
2024Q3
73
15.85M
39.34%
-1.46M
2024Q2
85
16.08M
39.89%
-939.10K
2024Q1
128
16.18M
41.46%
-1.22M
2023Q4
143
15.76M
40.39%
-1.74M
2023Q3
172
17.23M
44.26%
-3.36M
2023Q2
182
17.28M
44.39%
-4.16M
2023Q1
198
17.53M
45.04%
-4.14M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Decheng Capital LLC
4.88M
12.11%
-75.49K
-1.52%
Mar 31, 2025
Huang (Lan)
4.26M
10.58%
--
--
Feb 28, 2025
Jia (Linqing)
1.78M
4.43%
+4.00
+0.00%
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
115.97K
0.29%
-1.09K
-0.93%
Mar 31, 2025
BlackRock Financial Management, Inc.
90.54K
0.22%
--
--
Mar 31, 2025
Fabbio (Patrick)
53.86K
0.13%
+29.27K
+119.03%
Feb 28, 2025
Majeti (Jiangwen)
50.91K
0.13%
--
--
Feb 28, 2025
UBS Switzerland AG
34.93K
0.09%
-17.48K
-33.35%
Mar 31, 2025
Tanaka Capital Management, Inc.
26.30K
0.07%
-3.18K
-10.78%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
